Antiretroviral News and Research

RSS

AIDS 2010: Number of HIV positive patients on arvs grew to 5.2m in 2009 with 10m still in need, who says

"The number of HIV-positive people receiving antiretroviral drugs [ARVs] for their infections jumped by more than a quarter in 2009, growing from 4 million to 5.2 million, the World Health Organization said Monday at the International AIDS Conference in Vienna," the Los Angeles Times reports (7/19).

21 Jul 2010

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

Gilead Sciences, Inc. announced today its results of operations for the quarter ended June 30, 2010. Total revenues for the second quarter of 2010 were $1.93 billion, up 17 percent compared to total revenues of $1.65 billion for the second quarter of 2009. Net income for the second quarter of 2010 was $712.1 million, or $0.79 per diluted share, compared to net income for the second quarter of 2009 of $571.4 million, or $0.61 per diluted share.

21 Jul 2010

HIV – Rising menace

Nevirapine is considered to be an effective drug that can prevent HIV infection in babies born to mothers with HIV. However a new study shows that only about half of babies born to mothers with HIV receive the drug. The study appeared in the July 21 HIV/AIDS themed issue of the Journal of the American Medical Association.

20 Jul 2010

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

Researchers who conducted a study testing a vaginal microbicide with an antiretroviral (ARV) drug called tenofovir found its use before and after sex was significantly more protective against HIV infection than a placebo gel among women at high risk of HIV. Results of the study, known as CAPRISA 004, are to be reported at the International AIDS Conference (AIDS 2010) in Vienna and published online by the journal Science.

20 Jul 2010

WHO announces new approaches to HIV prevention and treatment among children

Efforts worldwide on access to treatment for children with HIV have reached a new milestone, with 355 000 children receiving life-saving HIV treatment at the end of 2009, compared to 276 000 at the end of 2008; but many more lives could be saved if more infants started on medication earlier according to new recommendations from the World Health Organization (WHO).

20 Jul 2010

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

Results of an advanced clinical trial of an antiretroviral-based microbicide candidate are being announced at the International AIDS Conference in Vienna, Austria. The CAPRISA 004 trial, which tested the safety and effectiveness of 1% tenofovir gel among nearly 900 women at two sites in South Africa, found that using the gel before and after sex provided moderate protection against sexually transmitted HIV.

20 Jul 2010

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

"This is a historic day for HIV prevention research. The CAPRISA 004 results are the first clinical evidence that a microbicide gel can help to prevent sexual transmission of HIV infection," said AVAC Executive Director Mitchell Warren, reacting to the results of the landmark microbicide trial presented today at the International AIDS Conference in Vienna.

20 Jul 2010

Bill Gates calls for renewed focus on reducing new HIV infections

Speaking to the 18th International AIDS Conference today, Bill Gates called on all countries to keep up the fight against HIV/AIDS, saying the world has an historic opportunity to "change the face of AIDS." Mr. Gates said current efforts to treat people with HIV are saving millions of lives, and urged a renewed focus on reducing annual new HIV infections up to 90% by 2031, the year that will mark 50 years of the AIDS epidemic.

20 Jul 2010

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Argos Therapeutics today announced that, in an interim analysis of a Phase 2 trial, its Arcelis immunotherapy targeted at HIV, AGS-004, demonstrated a significant reduction in viral load and a delay in viral rebound kinetics during a 12-week antiretroviral treatment interruption (ARTI) when compared to pre-ART viral loads.

20 Jul 2010

Education campaign positively impacts attitudes, behaviour of young people towards HIV/AIDS

INTERNATIONAL AIDS CONFERENCE 2010 -- MTV, the U.S. President's Emergency Plan for AIDS Relief and UNICEF today unveiled at INTERNATIONAL AIDS CONFERENCE 2010, new research on its Staying Alive Ignite Campaign at, which found that creating compelling pro-social entertainment for young people can positively impact attitudes and behaviour towards HIV and AIDS.

20 Jul 2010

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

Researchers have achieved an important scientific breakthrough in the fight against HIV and genital herpes with a vaginal gel that significantly reduces a woman's risk of being infected with these viruses. The results of the ground-breaking safety and effectiveness study of an antiretroviral microbicide gel study were reported today by the Centre for the AIDS Programme of Research in South Africa at the XVIII International AIDS Conference in Vienna, Austria.

20 Jul 2010

USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women

USAID is proud to be the major funder of the first-ever proof of concept that a microbicide can effectively and safely reduce the transmission of HIV from men to vulnerable women. An achievement of this magnitude could not have been possible without collaboration among governments, scientists, communities, and individual women at risk of HIV.

20 Jul 2010

WHO advises earlier treatment for people with HIV

An estimated 5.2 million people were receiving life-saving HIV treatment at the end of 2009, according to the latest update from the WHO. WHO estimates that 1.2 million people started treatment in 2009, bringing the total number of people receiving treatment to 5.2 million, compared to 4 million at the end of 2008.

20 Jul 2010

BC-CfE study suggests HAART may prevent transmission, spread of HIV

The BC Centre of Excellence in HIV/AIDS published an important study today in the globally respected Lancet medical journal. The study strongly reinforces the view that the benefits of highly active antiretroviral therapy extend beyond treatment of the virus to significantly preventing the transmission and spread of HIV.

20 Jul 2010

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

"Treating HIV patients with cocktails of AIDS drugs helps to stop them spreading the infection further and more than halved the number of new HIV diagnoses in a study in Canada, scientists said on Sunday," Reuters reports.

20 Jul 2010

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Today at the XVIII International AIDS Conference in Vienna, Austria, members of the International Rectal Microbicide Advocates (IRMA) and thousands of other HIV advocates and scientists cheered a long-awaited, much anticipated success in the quest for new HIV prevention technologies. Researchers announced that a vaginal gel has been shown to significantly reduce a woman's risk of being infected with HIV and genital herpes

20 Jul 2010

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Abbott today presented 48-week findings comparing an HIV regimen of its protease inhibitor (PI), Kaletra® (lopinavir/ritonavir), and Merck's integrase inhibitor, Isentress® (raltegravir), to a traditional HIV regimen of Kaletra and the nucleotide/nucleoside reverse transcriptase inhibitors (NRTIs) in Truvada® (tenofovir and emtricitabine) in antiretroviral-naive adult patients. Efficacy data were collected over the first 48 weeks of the 96-week PROGRESS (PROtease/InteGRasE Simplification Study) study.

20 Jul 2010

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

Only about half of infants born to HIV-infected mothers in some African countries receive a minimum preventive dose of the drug nevirapine to help reduce the risk of mother-to-child HIV transmission, according to a study in the July 21 issue of JAMA, a theme issue on HIV/AIDS.

20 Jul 2010

A look into HIV related issues

According to a report from US health officials, the poorer neighborhoods of America's cities harbour at least 1 in 50 heterosexual adults infected with HIV. These figures are more than elsewhere in the country. According to the research team from the U.S. Centers for Disease Control and Prevention (CDC), being poor and getting HIV are linked and this was regardless of race or ethnicity.

19 Jul 2010

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Genetic Immunity, a US/Hungarian biopharmaceutical company developing nanomedicine-based immunotherapies for HIV/AIDS and other chronic diseases, is releasing Phase II data on the Company's novel DermaVir therapeutic vaccine for HIV/AIDS during the XVIII International AIDS Conference this week in Vienna, Austria. DermaVir, the first dendritic cell-targeting topical HIV vaccine candidate, employs nanotechnology to induce multi-faceted and long-lived immune responses capable of eliminating HIV infected cells.

19 Jul 2010

Antiretroviral News and Research

AIDS 2010: Number of HIV positive patients on arvs grew to 5.2m in 2009 with 10m still in need, who says

Gilead Sciences second-quarter total revenues increase 17% to $1.93 billion

HIV – Rising menace

Tenofovir gel reduces HIV by 39% in women: CAPRISA 004 study

WHO announces new approaches to HIV prevention and treatment among children

Global Campaign for Microbicides praises CAPRISA 004 gel trial for women's HIV prevention

AVAC applauds CAPRISA 004 microbicide gel trial for preventing sexual transmission of HIV infection

Bill Gates calls for renewed focus on reducing new HIV infections

Argos' Arcelis immunotherapy reduces viral load in interim analysis of Phase 2 HIV trial

Education campaign positively impacts attitudes, behaviour of young people towards HIV/AIDS

Researchers make scientific breakthrough in fight against HIV, genital herpes with a vaginal gel

USAID Administrator issues statement on CAPRISA 004 trial for preventing HIV infection in women

WHO advises earlier treatment for people with HIV

BC-CfE study suggests HAART may prevent transmission, spread of HIV

AIDS 2010 studies, releases: Treating HIV-positive patients with ARVs drove down number of new HIV infections, study finds

New microbicide gel reduces woman's risk of being infected with HIV, genital herpes

Abbott presents 48-week PROGRESS study results at 28th International AIDS Conference

Infants in African countries receive minimum help to reduce risk of mother-to-child HIV transmission: Study

A look into HIV related issues

Phase II data on Genetic Immunity's DermaVir vaccine to be presented at XVIII International AIDS Conference

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News